CONTENTS

S. No  Title  Page

Abbreviations  i
Abstract  iii

CHAPTER:1 INTRODUCTION

1.0 Introduction

1.1 Cancer  1

1.2 Cisplatin  3
  1.2.1 Discovery of cisplatin and its chemistry  3
  1.2.2 Chemistry  5
  1.2.3 Mechanism of action  6
  1.2.4 Side effects  9
    1.2.4.1 Ototoxicity  10
    1.2.4.2 Nephrotoxicity  10
    1.2.4.3 Neurotoxicity  11
  1.2.5 Drug resistance  12
  1.2.6 Analogues  13

1.3 Drug delivery approach  14
  1.3.1 Nanoparticle mediated drug delivery systems  15
    1.3.1.1 Advantages  16
    1.3.1.2 Characteristics important for drug delivery using nanoparticles  17
      1.3.1.2.1 Particle size  17
1.3.1.2.2 Surface properties of nanoparticles 18
1.3.1.3 Nanoparticle mediated drug delivery 19
1.3.1.3.1 Targeted Delivery of Therapeutic Nanoparticles 19
   1.3.1.3.1.1 Passive Targeting 19
   1.3.1.3.1.2 EPR effect 19
   1.3.1.3.1.3 Tumor Microenvironment 22
   1.3.1.3.1.4 Active Targeting 22
1.3.1.3.2 Types of nanoparticles as Drug Delivery Systems 24
   1.3.1.3.2.1 Dendrimer 26
   1.3.1.3.2.2 Structure 28
      1.3.1.3.2.3 Synthesis 29
      1.3.1.3.2.4 Advantages of Dendrimers 32
      1.3.1.3.2.5 Types of Dendrimers 34
      1.3.1.3.2.6 Pharmaceutical applications of dendrimers 34
   1.3.1.3.2.7 PAMAM dendrimers 35
      1.3.1.3.2.7.1 PAMAM dendrimers in drug delivery 36
      1.3.1.3.2.7.2 Drug encapsulation 36
      1.3.1.3.2.7.3 Drug conjugation or covalent interaction 37
      1.3.1.3.2.7.4 Electrostatic interaction 37
   1.3.1.3.2.8 Current clinical status of PAMAM dendrimer 39
1.4 References 41
CHAPTER 2 MATERIALS AND METHODS

2.0 Materials 55

2.1 Methods 58

2.1.1 Experimental setup for synthesis 58

2.1.2 Analytical Techniques 58

2.1.2.1 Thin layer chromatography (TLC) 58

2.1.2.2 Column chromatography 59

2.1.2.3 High Performance Liquid chromatography (HPLC) 59

2.1.2.4 Reverse phase-HPLC 59

2.1.2.5 Size exclusion chromatography (SEC) 59

2.1.2.6 FTIR spectrometer 60

2.1.2.7 Nuclear magnetic resonance (NMR) spectroscopy 60

2.1.2.8 Mass spectrometry (MS) 60

2.1.2.9 Dynamic Light Scattering (DLS) 61

2.1.2.10 Potentiometer 61

2.1.2.11 UV-Vis Spectrophotometer 61

2.1.2.12 Inductively Coupled Plasma-Optical Emission Spectrometer (ICP-OES) 61

2.1.2.13 Instruments 61

2.1.2.14 Ultrafiltration device 62

2.1.2.15 Institutional Ethics Committee (IEC) 62

2.1.2.16 Institutional Animal Ethics Committee (IAEC) 62

2.1.2.17 Media preparation 62
2.1.2.18 Maintenance of cell lines 63
2.1.2.19 Freezing of cells 63
2.1.2.20 Thawing of cells 63
2.1.2.21 TEM 64
2.1.2.22 Flow cytometry 64
2.1.2.23 SCID mice models for evaluating the antitumor 64
efficacy of targeted dendrimer cisplatin conjugates
2.1.2.24 Statistical analysis 65

2.2 References 65

CHAPTER 3 SYNTHESIS AND CHARACTERIZATION OF
PAMAM AND DGA-PAMAM DENDRIMERS

3.0 Introduction 66
3.1 Methodology 66
3.2 Results 72
3.3 Discussion 92
3.4 Conclusion 93
3.5 References 94

CHAPTER 4 IN VITRO CYTOTOXICITY STUDIES FOR DGA-
PAMAM-CISPLATIN CONJUGATES

4.0 Introduction 96
4.1 Methodology 98
4.2 Results 101
4.3 Discussion 111
CHAPTER 5 TARGETING STUDIES OF DGA-PAMAM-CISPLATIN CONJUGATES WITH HERCEPTIN AND EVALUATION OF IT’S IN VITRO CYTOTOXICITY

5.0 Introduction 117
5.1 Methodology 119
5.2 Results 126
5.3 Discussion 141
5.4 Conclusion 143
5.5 References 144

CHAPTER 6 IN VIVO EFFICACY OF HERCEPTIN TARGETED DGA-PAMAM DENDRIMERS

6.0 Introduction 150
6.1 Methodology 151
6.2 Results 152
6.3 Discussion 154
6.4 Conclusion 154
6.5 References 155
CHAPTER 7 BIOCOMPATIBILITY OF DGA-PAMAM DENDRIMERS

7.0 Introduction 156
7.1 Methodology 157
7.2 Results 158
7.3 Discussion 161
7.4 Conclusion 161
7.5 References 162

SUMMARY OF THE THESIS 164

PUBLICATIONS 165

PRESENTATIONS 166

ANNEXURE